Jolla Value Stock - Dividend - Research Selection
Market price: 6,20 USD
La Jolla Pharmaceutical Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||28.244.000|
|Free cash flow||28.235.000|
|Liabilities & Shareholders equity||101.230.000|
|Diluted shares outstanding||27.497.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||170.481.408,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2014-01-14,1.000000/50.000000; 2012-02-17,1.000000/100.000000; 2011-04-15,1.000000/100.000000; 2005-12-22,1.000000/5.000000|
Description of the company
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.